As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Actuate Therapeutics, Inc. The largest reported stake is Voss Capital, LP's, at 7.7%. 3 filings are on record since December 17, 2025 (Schedule 13G/A, April 22, 2026).
Sell to companies like Actuate Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Hexstone Capital LLC · Sole voting: 0 · Shared voting: 4,225,352 · Sole dispositive: 0 · Shared dispositive: 4,225,352 · SCHEDULE 13G, 2026-10-30
- · Reporting person: Voss Capital, LP · Sole voting: 1,400,000 · Shared voting: 414,263 · Sole dispositive: 1,400,000 · Shared dispositive: 414,263 · SCHEDULE 13G/A, 2026-04-22
- · Holder: Voss Capital, LP · Percent: 5.3% · SCHEDULE 13G
Actuate Therapeutics, Inc. has 3 Schedule 13D or 13G filings on record since 2025-12-17. 2 holders' latest filing reports 5% or more of common stock, par value $0.000001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Voss Capital, LP | 7.7% | 1,814,263 | SCHEDULE 13G/A, 2026-04-22 | 2026-03-31 |
| Hexstone Capital LLC | 7.7% | 4,225,352 | SCHEDULE 13G, 2026-10-30 | 2026-10-27 |
Holding shares or following this stake? See who's behind Actuate Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Actuate Therapeutics, Inc. and the records around it.
Actuate Therapeutics, Inc. elsewhere on the record
- Leadership changes May 2026
- Form D filing Jul 2025
- Who owns it
Companies that share a holder
- Hexstone Capital LLC also filed stake reports on 6 other companies: Jet.AI Inc. (Nov 2026), Global Mofy AI Ltd (May 2026), Cellectar Biosciences, Inc. (Feb 2026)
- Voss Capital, LP also filed stake reports on 13 other companies: Five9, Inc. (Oct 2026), Cellebrite DI Ltd. (Aug 2026), ALTA EQUIPMENT GROUP INC. (Jul 2026)
Watch Actuate Therapeutics, Inc.
Get an email when Actuate Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Actuate Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Actuate Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Actuate Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Voss Capital, LP | 1,400,000 | 414,263 | 1,400,000 | 414,263 | SCHEDULE 13G/A, 2026-04-22 |
| Cocke Travis W. | 1,400,000 | 414,263 | 1,400,000 | 414,263 | SCHEDULE 13G/A, 2026-04-22 |
| Voss Advisors GP, LLC | 350,000 | 0 | 350,000 | 0 | SCHEDULE 13G/A, 2026-04-22 |
| Voss Value Master Fund, LP | 300,000 | 0 | 300,000 | 0 | SCHEDULE 13G/A, 2026-04-22 |
| Voss Value-Oriented Special Situations Fund, LP | 50,000 | 0 | 50,000 | 0 | SCHEDULE 13G/A, 2026-04-22 |
| Hexstone Capital LLC | 0 | 4,225,352 | 0 | 4,225,352 | SCHEDULE 13G, 2026-10-30 |
| Brendan O'Neil | 0 | 4,225,352 | 0 | 4,225,352 | SCHEDULE 13G, 2026-10-30 |
The latest filing identifies Actuate Therapeutics, Inc. by CUSIP 005083100 and gives its principal executive office as 4851 Tamiami Trail North, Suite 200, Naples, FL 34103 (SCHEDULE 13G, 2026-10-30).
What the percentages are based on
The aggregate percentage of the Shares reported owned by each person named herein is based upon 23,709,943 Shares outstanding as of March 25, 2026, which is the total number of Shares outstanding as disclosed in the Issuer's Form 10K filed with the Securities and Exchange Commission on March 26, 2026.Voss Capital, LP, SCHEDULE 13G/A, 2026-04-22
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-12-17 | Voss Capital, LP | 5.3% | SCHEDULE 13G |
| 2026-04-22 | Voss Capital, LP | 7.7% | SCHEDULE 13G/A |
| 2026-10-30 | Hexstone Capital LLC | 7.7% | SCHEDULE 13G |
Questions about who owns Actuate Therapeutics, Inc.
Who owns Actuate Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Actuate Therapeutics, Inc.: Voss Capital, LP (7.7%, Schedule 13G/A, filed 2026-04-22) and Hexstone Capital LLC (7.7%, Schedule 13G, filed 2026-10-30).
Who are the largest shareholders of Actuate Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Actuate Therapeutics, Inc. on this page are Voss Capital, LP (7.7%) and Hexstone Capital LLC (7.7%).
When did Voss Capital, LP buy into Actuate Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Voss Capital, LP on this page is the Schedule 13G, filed 2025-12-17, reporting 5.3%; its latest, Schedule 13G/A filed 2026-04-22, reports 7.7%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Actuate Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 19, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| October 14, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| October 6, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| May 6, 2026 | Leadership change: Martin H. Huber appointed, and 1 more | — | Leadership changes | Source |
| July 25, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| July 7, 2025 | Form D, private offering | $4.67M sold | Form D page | Source |
| April 10, 2025 | Form D, private offering | — | Form D page | Source |
| March 28, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| August 13, 2024 | IPO filing, Form 424B4 | $8 a share | IPO filings | Source |
| July 23, 2024 | IPO filing, Form S-1/A | — | IPO filings | Source |
| July 19, 2024 | IPO filing, Form S-1/A | — | IPO filings | Source |
| July 16, 2024 | IPO filing, Form S-1/A | — | IPO filings | Source |
Tools for this story
Each opens in a new tab, filled in for Actuate Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.